Try Alerts Free   |   Login
Health Care › Arrangement Of Transportation Of Freight And Cargo

CYRX Price Correlated With Financials For CryoPort

Free historical financial statements for CryoPort Inc.. See how revenue, income, cash flow, and balance sheet financials have changed over 44 quarters since 2011. Compare with CYRX stock chart to see long term trends.

CYRX Stock Compared to Quarterly

CYRX Income Statement

Revenue, Net:52302000
Revenue Per Share:1.0532
Cost of Goods & Services Sold:29961000
Gross Profit:22341000
Selling, General & Admin Expense:26622000
Research & Development Expense:3538000
Total Operating Expenses:30160000
Operating Income:-13063000
Income Taxes:341000
Net Income:-15404000
Earnings Per Share, Basic:-0.31
Shares Outstanding, Basic Avg:49660579

CYRX Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:5365000
Net Cash from Operations:524000
Net Cash from Operations Per Share:0.0106
Repurchases/Buybacks Common Stock:8349000
Net Cash from Financing Activities:-8049000
Property, Plant & Equipment Purchases:4245000
Net Cash from Investing Activities:3050000
Net Change in Cash & Equivalents:-4653000

CYRX Balance Sheet

Cash and Cash Equivalents:599511000
Short-Term Investments:465063000
Accounts Receivable, Net:35837000
Total Current Assets:665773000
Property, Plant & Equipment, Net:50734000
Total Assets:1081332000
Total Short-Term Liabilities:44441000
Total Liabilities:471898000
Note 1. Management’s Representation and Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared by Cryoport, Inc. (the “Company”, “Cryoport”, “our” or “we”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statement presentation. However, the Company believes that the disclosures are adequate to make the information presented not misleading. In the opinion of management, all adjustments (consisting primarily of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. The unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The Company has evaluated subsequent events through the date of this filing and determined that no subsequent events have occurred that would require recognition in the unaudited condensed consolidated financial statements or disclosure in the notes thereto other than as disclosed in the accompanying notes.

Data imported from CryoPort Inc. SEC filings. Check original filings before making any investment decision.